Innovative RNA Therapy Targets Cardiac Repair

Scientists at Columbia University have developed a groundbreaking therapy designed to mend heart damage following a cardiac event. The study, published in Nature Biomedical Engineering, outlines a unique two-step strategy that utilizes skeletal muscle to generate a healing molecule that activates upon reaching the injured heart.

Overcoming Natural Limitations

Unlike many other organs, the adult human heart possesses a very limited capacity for self-repair. Lead author Ke Cheng, a professor of biomedical engineering at Columbia, noted that dead muscle is typically replaced by stiff scar tissue, which often results in heart failure.

Researchers drew inspiration from newborns, whose hearts can spontaneously regenerate for a short period. Cheng explained that while neonatal hearts naturally produce healing molecules after an injury, adult hearts cannot produce enough on their own. The new treatment supplements this deficiency by mimicking these natural processes.

The Role of the ANP Protein

The core of this therapy is a protein known as ANP, which serves as a natural repair mechanism. Under normal circumstances, ANP is ineffective as a drug because it dissolves in the bloodstream before it can reach the heart.

To bypass this, researchers used a specialized RNA injection to turn skeletal muscles in the arm or leg into a production factory. These muscles are instructed to create an inactive, "sleeping" version of the ANP protein. This version travels safely through the blood until it reaches the heart, where a specific enzyme acts as a key to activate the protein for precise repair.

Promising Results in Preclinical Trials

  • Effective Healing: In trials with small and large animals, a single limb injection successfully reduced scarring and improved heart function.
  • Extended Duration: The use of self-amplifying RNA allows the treatment to continue producing the healing protein for at least four weeks.
  • Delayed Administration: The therapy remained effective even when administered a week after the initial injury, offering potential benefits for patients who cannot receive immediate care.

Cheng highlighted that this method avoids the significant risks associated with injecting treatments directly into the heart muscle. However, the researchers emphasize that the study has only been conducted on animals thus far. Future clinical trials are essential to determine if human hearts will respond similarly and to ensure that the prolonged presence of the protein does not cause unintended side effects.